Title Disease modifying therapy after autologous haematopoietic stem cell transplantation in multiple sclerosis patients: 10-years follow-up data from Lithuania
Authors Giedraitienė, Nataša ; Kaubrys, Gintaras Ferdinandas ; Kizlaitienė, Rasa ; Pečeliūnas, Valdas ; Dementavičienė, Jūratė ; Žučenka, Andrius ; Griškevičius, Laimonas
DOI 10.1016/j.msard.2025.106728
Full Text Download
Is Part of Multiple sclerosis and related disorders.. Amsterdam : Elsevier B.V.. 2025, vol. 103, art. no. 106728, p. [1-7].. ISSN 2211-0348. eISSN 2211-0356
Keywords [eng] autologous haematopoietic stem cell transplantation ; disease modifying therapy ; relapsing-remitting multiple sclerosis
Abstract [eng] Background: There is limited information reported on the management of disease modifying treatment (DMT) in patients with multiple sclerosis (MS) who have been treated with autologous hematopoietic stem cell transplantation (AHSCT). Methods: We conducted a single-centre prospective study of patients with highly active relapsing-remitting MS who underwent AHSCT in Lithuania from May 2014 till January 2025. Results: Forty-two patients were selected and treated with AHSCT. 65.0 % of patients who underwent AHSCT achieved No Evidence of Disease Activity-3 (NEDA-3) over a 65-month median follow-up period. 35.6 % of patients experienced improvement in their Expanded Disability Status Scale (EDSS) scores by the third month post-transplant, and this improvement was maintained throughout the follow-up period. Twelve patients (28.5 %) who experienced disease activity after AHSCT were treated with DMT: eight patients (19.0 %) were treated with ocrelizumab, and in four patients (9.5 %), SPMS was diagnosed and patients were treated with siponimod. Five patients who were treated with ocrelizumab after AHSCT achieved NEDA-3, three of whom had been on DMT for >12 months. Conclusion: The majority of patients maintained NEDA-3 up to five years after AHSCT. Patients who did not achieve NEDA-3 were successfully treated with high-efficacy DMT. No mortality was observed in our cohort. These findings support the efficacy and safety of AHSCT, as well as the use of DMT following AHSCT, in patients with highly active relapsing-remitting MS.
Published Amsterdam : Elsevier B.V
Type Journal article
Language English
Publication date 2025
CC license CC license description